Asset
COM-701
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06888921 | phase1_2 | recruiting | 2025-07-21 | 2027-03-01 | Compugen Ltd | A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer |
| NCT03667716 | phase1 | completed | 2018-09-06 | 2024-01-30 | Compugen Ltd | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. |
FDA applications (0)
This company has no applications containing this asset.